The press release is from the underwriter, not the issuer. Monitor Vogenx for its first earnings report as a public company and any pipeline updates for PBH/gastroparesis. The IPO provides ~$81M in cash runway for a clinical-stage biotech.
Price Chart
Executive Summary
JonesTrading Institutional Services acted as sole book-running manager for Vogenx's $81.3 million IPO of 6.25 million shares at $13.00 per share. The offering closed on August 13, 2026, and the stock began trading on Nasdaq under VOGX on August 12, 2026. This is a capital markets advisory announcement by the underwriter, not a Vogenx disclosure.
Key Financial Metrics
Key Facts
- IPO size: $81.3 million gross proceeds
- 6,250,000 shares issued at $13.00 per share
- Priced at high end of proposed range
- JonesTrading was sole book-running manager
- Vogenx is a clinical-stage biopharma focused on metabolism disorders (PBH, gastroparesis)
- Stock began trading on Nasdaq on August 12, 2026; offering closed August 13, 2026
Financial Impact
$81.3M gross proceeds to Vogenx from the IPO, net of underwriting discounts and expenses.
Risk Factors
- Clinical-stage biotech: no approved products, pipeline risk for PBH and gastroparesis programs
- IPO priced at high end — near-term upside may be limited as lock-up expiration approaches (~180 days from close)
- Low trading volume typical for newly public micro-cap names
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302853039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $17.56 | awaiting T+20 | — | $17.45 (−0.63%) |
Aug 17, 2026 10w ago | Press Release | $15.75 $32.21 | ▲ +104.51% | ▲ +106.49% | $17.45 (+10.79%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.45 (+34.23%) |
Aug 11, 2026 10w ago | 3 | $13.00 $29.86 | ▲ +129.69% | ▲ +131.59% | $17.45 (+34.23%) |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 29, 2026 12w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers